SEC Form 4 · accession 0001209191-19-011378
Outlook Therapeutics, Inc. · OTLK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawrence A Kenyon
Officer — CEO, Pres, CFO, Treas & Secy · Director
Period of report
Feb 19, 2019
Accepted (ET)
Feb 19, 2019 · 8:24 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001649989
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $1.32 | Feb 19, 2019 | A | 800,000 | A | — | Feb 19, 2029 | Common Stock | 800,000 | 800,000 | D |
Explanation of responses
- F1The shares underlying the option shall vest in four equal installments beginning on February 19, 2020 such that the option shall be vested in full on February 19, 2023, subject to the Reporting Person providing continuous service to the Issuer on each such date. Vesting may be accelerated in the event of (a) a change in control as defined in the Issuer's 2015 Equity Incentive Plan and (b) the achievement of certain pre-defined corporate objectives, in each case subject to the Reporting Person providing continuous service to the Issuer through such event.